Related Experiment Video
Updated: Apr 21, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.5K
Steady progress on Parkinson's disease.
P & T : a Peer-Reviewed Journal for Formulary Management
|October 23, 2014
Summary
Parkinson's disease treatments are projected to reach $3.56 billion in global sales for 2022. Pharmaceutical companies are actively developing new therapies and improving existing Parkinson's disease medications.
Area of Science:
- Neurology
- Pharmacology
- Health Economics
Background:
- Parkinson's disease is a progressive neurodegenerative disorder.
- Current treatments aim to manage symptoms but do not halt disease progression.
- The global market for Parkinson's disease therapeutics is substantial and growing.
Purpose of the Study:
- To analyze the projected global sales for Parkinson's disease treatments in 2022.
- To highlight the ongoing innovation in pharmaceutical development for Parkinson's disease.
Main Methods:
- Market analysis based on sales projections.
- Review of pharmaceutical industry trends in drug reformulation and new drug development.
Main Results:
- Global sales for Parkinson's disease treatments are forecasted to reach $3.56 billion in 2022.
- Significant investment in both reformulating existing drugs and developing novel therapeutic agents is evident.
Conclusions:
- The Parkinson's disease market demonstrates robust economic activity.
- Continuous innovation in drug development is a key characteristic of this therapeutic area.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
01:24Parkinson Disease l: Introduction
6
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
6
01:24Parkinson Disease ll: Pathophysiology
11
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
11
01:11Alterations in Muscle Tone lll
19
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
19
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K